Last updated: February 20, 2026
What is the Drug with NDC 71921-0242?
NDC 71921-0242 corresponds to Xywav, a calcium, magnesium, and sodium oxybate formulation approved by the FDA in July 2021 for treating narcolepsy in adults. It is a low-sodium alternative to existing oxybate therapies.
Market Landscape
Indication and Competitive Position
Xywav competes primarily with Soma (sodium oxybate, also known as Xyrem) and other narcolepsy treatments such as modafinil and armodafinil. The market size for narcolepsy drugs in the U.S. reached approximately $350 million in 2022.
Market Penetration and Key Drivers
- Clinical Need: Narcolepsy affects about 1 in 2,000 individuals, with a registry of roughly 100,000 patients in the U.S.
- Treatment Complexity: Xywav offers a lower sodium content than Xyrem, appealing to patients with hypertension or cardiovascular risks.
- Physician Adoption: Limited initial prescriber base due to rarity of the condition and the need for specialized treatment.
- Pricing and Reimbursement: Discounted under significant patient assistance programs. Wholesale acquisition cost (WAC) for Xywav is approximately $45,000 annually.
Distribution Channels
Xywav is marketed through specialty pharmacies, with initial focus on large academic centers and sleep clinics. Insurance coverage is prevalent, but prior authorization remains a barrier.
Price Projections
Current Pricing
- WAC: ~$45,000 per patient annually.
- List Price: Similar to WAC, with negotiated payer discounts.
Long-term Price Trends
- Short-term (1-2 years): Stable pricing due to limited competition.
- Mid-term (3-5 years): Potential price erosion of 5-10% driven by increased competition and biosimilar entries.
- Long-term (5+ years): Price stabilization expected, with possible reductions due to market saturation and payer pressure.
Market Share Growth Estimates
| Year |
Estimated Market Share |
Revenue (USD Millions) |
| 2023 |
15% |
52.5 |
| 2024 |
20% |
70 |
| 2025 |
25% |
87.5 |
| 2026 |
30% |
105 |
| 2027 |
35% |
122.5 |
Assuming a total narcolepsy drug market of $350 million in 2022, with modest growth.
Price Sensitivity Factors
- Market Exclusivity: Patent protections until at least 2030 secure pricing power.
- Regulatory Changes: New approvals for alternative formulations or generics could pressure prices downward.
- Reimbursement Policies: Shifts toward value-based compensation may influence pricing models.
Competitive Analysis
Key Competitors
| Product |
Features |
Price (USD) |
Market Position |
| Xyrem (sodium oxybate) |
Established, high sodium content |
~$43,000 |
Leading narcolepsy treatment |
| Alzheimer’s drugs (off-label) |
Not directly comparable |
N/A |
Limited competition |
| Emerging biosimilars or generics |
Potential in next 3-5 years |
Potentially 15-20% lower |
Market pressure on prices |
Differentiators for Xywav
- Lower sodium content reduces cardiovascular risks.
- Recent FDA approval provides early mover advantage.
- Pricing is comparable to Xyrem, with discounts built into negotiations.
Market Entry Barriers
- Regulatory Complexity: Approval process for new formulations.
- Manufacturing Access: Specialized production for oxybate compounds.
- Prescriber Awareness: Need for education campaigns.
- Distribution Agreements: Exclusivity with specialty pharmacies.
Regulatory and Policy Impact
- Pending FDA guidance on oxybate formulations could influence future pricing or approval pathways.
- Payer mandates for prior authorization can restrict market expansion.
Summary Outlook
- Xywav is well-positioned within a niche market initially dominated by Xyrem.
- Price stability relies on maintaining patent and market exclusivity and managing reimbursement negotiations.
- Moderate price erosion expected over five years as competition increases.
- The potential for biosimilar or generic entrants after patent expiry can significantly impact pricing.
Key Takeaways
- NDC 71921-0242 (Xywav) commands a premium price (~$45,000/year) driven by unique formulation benefits.
- Market share is expected to grow modestly in the next five years, reaching approximately 35%.
- Price erosion of 5-10% is anticipated due to increasing competition.
- Market expansion hinges on prescriber education, insurance coverage, and regulatory developments.
- Long-term profitability will depend on patent protections, market exclusivity, and adoption rates.
FAQs
What factors could lead to a significant price reduction for Xywav?
Entry of generic competitors post-patent expiry, changes in reimbursement policies, or breakthroughs with alternative treatments could lower prices.
How does Xywav's lower sodium content influence market adoption?
Clinicians may prefer it for patients with cardiovascular risks, increasing adoption among targeted patient populations.
What is the expected timeline for biosimilar entries?
Biosimilars are unlikely before 2028, depending on patent litigation and regulatory approval.
How vulnerable is Xywav to market erosion?
Moderately vulnerable; strong patent protections and clinically proven benefits support sustained pricing, but competition remains a threat.
Are there unmet needs that could expand this market?
Yes, enhancing formulations or new indications for oxybate therapy could drive growth beyond narcolepsy.
References
[1] FDA. (2021). FDA approves Xywav for narcolepsy.
[2] IQVIA. (2022). U.S. narcolepsy drug market report.
[3] MarketResearch.com. (2023). Future trends in narcolepsy treatments.
[4] Medicare & Medicaid Services. (2022). Reimbursement trends for sleep disorder treatments.
